At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers
In Brief
A Phase 2 clinical trial evaluating Computed Tomography, Iodine I 124, and 5 other interventions for Metastatic Thyroid Gland Carcinoma and 11 related conditions. Active but no longer recruiting, targeting 34 participants across 1 site.
Detailed Summary
This phase II trial studies how well trametinib works in increasing tumoral iodine incorporation in patients with thyroid cancer that has come back or spread to another place in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Study Details
Timeline
Interventions
Undergo iodine I-124 PET/CT
Undergo iodine I-124 PET/CT
Given PO
Correlative studies
Correlative studies
Undergo iodine I-124 PET/CT
Given PO